Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S.

J Clin Oncol. 2012 May 1;30(13):1415-21. doi: 10.1200/JCO.2011.34.8987. Epub 2011 Nov 28.

2.

Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.

Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S.

Cancer. 2008 Jun 15;112(12):2789-95. doi: 10.1002/cncr.23534.

3.

Risk factors for anthracycline-associated cardiotoxicity.

Reinbolt RE, Patel R, Pan X, Timmers CD, Pilarski R, Shapiro CL, Lustberg MB.

Support Care Cancer. 2016 May;24(5):2173-2180. doi: 10.1007/s00520-015-3008-y. Epub 2015 Nov 12.

4.

Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.

Wang X, Liu W, Sun CL, Armenian SH, Hakonarson H, Hageman L, Ding Y, Landier W, Blanco JG, Chen L, Quiñones A, Ferguson D, Winick N, Ginsberg JP, Keller F, Neglia JP, Desai S, Sklar CA, Castellino SM, Cherrick I, Dreyer ZE, Hudson MM, Robison LL, Yasui Y, Relling MV, Bhatia S.

J Clin Oncol. 2014 Mar 1;32(7):647-53. doi: 10.1200/JCO.2013.50.3557. Epub 2014 Jan 27.

5.

CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study.

Wang X, Sun CL, Quiñones-Lombraña A, Singh P, Landier W, Hageman L, Mather M, Rotter JI, Taylor KD, Chen YD, Armenian SH, Winick N, Ginsberg JP, Neglia JP, Oeffinger KC, Castellino SM, Dreyer ZE, Hudson MM, Robison LL, Blanco JG, Bhatia S.

J Clin Oncol. 2016 Mar 10;34(8):863-70. doi: 10.1200/JCO.2015.63.4550. Epub 2016 Jan 25.

6.

Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium.

J Clin Oncol. 2012 May 1;30(13):1422-8. doi: 10.1200/JCO.2010.34.3467. Epub 2011 Sep 6.

PMID:
21900104
7.

Single nucleotide polymorphisms and anthracycline cardiotoxicity in children: potential implications for adult oncology.

Atkins CD.

J Clin Oncol. 2012 Oct 1;30(28):3563; author reply 3563-4. Epub 2012 Aug 27. No abstract available.

PMID:
22927524
8.

Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.

Quiñones-Lombraña A, Ferguson D, Hageman Blair R, Kalabus JL, Redzematovic A, Blanco JG.

Pharm Res. 2014 Jul;31(7):1644-55. doi: 10.1007/s11095-013-1267-1. Epub 2014 Feb 22.

9.

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.

Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, Chowbay B.

Cancer Sci. 2008 Oct;99(10):2045-54. doi: 10.1111/j.1349-7006.2008.00903.x.

10.

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.

Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo YM, Iau P, Lee HS, Lee SC.

Pharmacogenet Genomics. 2008 Jul;18(7):621-31. doi: 10.1097/FPC.0b013e328301a869.

PMID:
18551042
11.

Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.

Ferguson DC, Cheng Q, Blanco JG.

Drug Metab Dispos. 2015 Jul;43(7):922-7. doi: 10.1124/dmd.115.064295. Epub 2015 Apr 27.

12.

Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study.

Henderson TO, Rajaraman P, Stovall M, Constine LS, Olive A, Smith SA, Mertens A, Meadows A, Neglia JP, Hammond S, Whitton J, Inskip PD, Robison LL, Diller L.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):224-30. doi: 10.1016/j.ijrobp.2011.11.022. Epub 2012 Jul 14.

13.

The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms.

Volkan-Salanci B, Aksoy H, Kiratli PÖ, Tülümen E, Güler N, Öksüzoglu B, Tokgözoğlu L, Erbaş B, Alikaşifoğlu M.

J Chemother. 2012 Oct;24(5):285-91. doi: 10.1179/1973947812Y.0000000037.

PMID:
23182048
14.

Pediatric quality of life in long-term survivors of childhood cancer treated with anthracyclines.

Ryerson AB, Wasilewski-Masker K, Border WL, Goodman M, Meacham L, Austin H, Marchak JG, Mertens AC.

Pediatr Blood Cancer. 2016 Dec;63(12):2205-2211. doi: 10.1002/pbc.26149. Epub 2016 Jul 21.

PMID:
27442487
15.

Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.

Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B.

J Cancer Surviv. 2012 Mar;6(1):95-101. doi: 10.1007/s11764-011-0186-6. Epub 2011 Jun 1.

16.

Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors.

Abosoudah I, Greenberg ML, Ness KK, Benson L, Nathan PC.

Pediatr Blood Cancer. 2011 Sep;57(3):467-72. doi: 10.1002/pbc.22989. Epub 2011 Jan 28.

PMID:
21280201
17.

Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study.

van der Pal HJ, van Dijk IW, Geskus RB, Kok WE, Koolen M, Sieswerda E, Oldenburger F, Koning CC, van Leeuwen FE, Caron HN, Kremer LC, van Dalen EC.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):213-22. doi: 10.1016/j.ijrobp.2014.09.010. Epub 2014 Oct 25.

PMID:
25442333
18.

Pregnancy-associated cardiomyopathy in survivors of childhood cancer.

Hines MR, Mulrooney DA, Hudson MM, Ness KK, Green DM, Howard SC, Krasin M, Metzger ML.

J Cancer Surviv. 2016 Feb;10(1):113-21. doi: 10.1007/s11764-015-0457-8. Epub 2015 Jun 5.

19.

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ.

J Clin Oncol. 2015 Nov 10;33(32):3774-80. doi: 10.1200/JCO.2015.61.5187. Epub 2015 Aug 24.

20.

Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.

Armenian SH, Ding Y, Mills G, Sun C, Venkataraman K, Wong FL, Neuhausen SL, Senitzer D, Wang S, Forman SJ, Bhatia S.

Br J Haematol. 2013 Oct;163(2):205-13. doi: 10.1111/bjh.12516. Epub 2013 Aug 8.

Supplemental Content

Support Center